Welcome to our dedicated page for Serina Therapeutics news (Ticker: ser), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Serina Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Serina Therapeutics's position in the market.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to three new non-executive employees. The grants, totaling 60,500 shares of common stock, were made on November 6, 2024, with exercise prices matching the closing stock price on that date. These options were approved as employment inducement awards under NYSE American's Company Guide Section 711(a). The options will vest over three years, with one-third vesting after the first year and the remaining two-thirds vesting in 24 monthly installments, contingent on continued employment.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company, announced its participation in the 14th Annual Injectables Summit in Boston, MA. The company's Chief Development Officer, Randall Moreadith, MD, PhD, will present alongside Enable Injections' Chief Commercial Officer Matthew Huddleston.
Their joint presentation, titled 'Patient-enabled Therapy for Advanced Parkinson's Disease', will focus on the collaboration between Serina's SER-252 and Enable Injections' enFuse Wearable Drug Delivery Platform. This partnership aims to provide advanced Parkinson's Disease patients with life-changing therapeutics through comfortable and convenient delivery methods.
Serina Therapeutics is known for developing its proprietary POZ Platform™ drug delivery technology, which is likely to be a key component in this collaborative effort to improve patient care and treatment outcomes.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Steve Ledger, Serina's Interim CEO, will present on September 11, 2024, at 12:00 p.m. ET.
Serina is known for developing its proprietary POZ Platform™ drug delivery technology. Investors and interested parties can access a live webcast of the presentation through the Investor section of Serina's website. An archived replay will also be available for a time after the event.
This presentation offers an opportunity for Serina to showcase its innovative technology and progress to a global investment audience, potentially impacting its stock performance and investor interest.
Serina Therapeutics (NYSE American: SER) reported Q2 2024 financial results and business highlights. Key points include:
1. Partnership with Enable Injections for SER-252 development in Parkinson's disease
2. Presentation of POZ-lipid immunogenicity data showing potential safety improvements for mRNA-LNP formulations
3. Appointment of Dr. Srini Tenjarla as SVP of CMC & Formulation
Financial highlights:
- Cash and equivalents: $6.1 million as of June 30, 2024
- Q2 2024 revenues: $51,000 (vs $7,000 in Q2 2023)
- Q2 2024 operating expenses: $3.9 million (vs $1 million in Q2 2023)
- Q2 2024 net income: $5.2 million or $0.61 per share (basic)
The company faces going concern considerations due to projected cash flows.
Serina Therapeutics (NYSE American: SER) is set to present groundbreaking data on its POZ-lipid technology at the 4th Annual mRNA-Based Therapeutics Summit in Boston, MA, from July 29-31, 2024. Dr. Randall Moreadith, Chief Development Officer, will showcase how this innovative approach could enhance the safety and efficacy of mRNA-LNP formulations.
The presentation, scheduled for July 29 at 9:00 AM ET, will highlight that POZ-lipid does not induce IgM or IgG antibody responses, even with repeated dosing in animal models. This is a significant advancement over current PEG-lipids used in mRNA vaccines, which can trigger anti-PEG antibody responses linked to serious adverse events, including life-threatening anaphylaxis.
Serina's technology has the potential to mitigate these risks, potentially improving the overall safety profile of mRNA-LNP medicines and opening new possibilities in the rapidly evolving field of mRNA therapeutics.
Serina Therapeutics (NYSE American: SER) has appointed Dr. Srini Tenjarla as the new Senior Vice President of CMC and Formulation. Dr. Tenjarla brings over 20 years of experience in drug development, joining from Takeda Pharmaceuticals where he was Vice President and Head of Drug Product Development and Process Chemistry Development/Outsourcing. He previously held leadership roles at Shire Pharmaceuticals.
Dr. Tenjarla's expertise spans formulation development across multiple modalities, including solid oral, injectables, controlled release, and ophthalmic formulations. He has a proven track record in advancing programs through clinical phases to NDA/BLA submission and approval. Dr. Tenjarla holds a Ph.D. in Pharmaceutical Sciences from the University of Houston and is recognized as a subject matter expert in formulation.
Serina Therapeutics reported its Q1 2024 financial results, highlighting significant developments. The company is advancing its lead drug candidate, SER-252, for advanced Parkinson’s Disease, with plans to submit an IND application in 2025. Serina completed its merger with AgeX Therapeutics and appointed Dr. Simba Gill as Executive Chairman. Financially, Serina increased its line of credit by $2.4 million and received an additional $525,000 in May 2024. Cash and equivalents totaled $8.8 million, with a net loss of $9.4 million for Q1 2024. Revenues were $5,000, and operating expenses increased to $2.3 million from $1 million in the same period in 2023. The company expressed concerns about its ability to meet financial obligations over the next year.
Summary not available.
Summary not available.